Market capitalization | $367.13m |
Enterprise Value | $257.48m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.05 |
P/S ratio (TTM) P/S ratio | 4.35 |
P/B ratio (TTM) P/B ratio | 1.22 |
Revenue growth (TTM) Revenue growth | -15.14% |
Revenue (TTM) Revenue | $84.33m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a REGENXBIO, Inc. forecast:
10 Analysts have issued a REGENXBIO, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 84 84 |
15%
15%
|
|
Gross Profit | 29 29 |
33%
33%
|
|
EBITDA | -227 -227 |
7%
7%
|
EBIT (Operating Income) EBIT | -244 -244 |
7%
7%
|
Net Profit | -239 -239 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Curran Simpson |
Employees | 344 |
Founded | 2008 |
Website | www.regenxbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.